Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30485007 | 1.00 | HDAC1 (0.50) | HDAC1AAK1ABL1HSP90AA1HSP90AB1 | |
| SCHEMBL5868853 | 0.89 | AAK1 (0.51) | HDAC1AAK1HSP90AA1HSP90AB1CYP17A1 | |
| SCHEMBL15550749 | 0.88 | AAK1 (0.46) | HDAC1AAK1ABL1HSP90AA1HSP90AB1 | |
| SCHEMBL3787046 | 0.86 | KMT2A (0.54) | HSP90AA1HSP90AB1PDK1PDK2PDK3 | |
| SCHEMBL17132206 | 0.85 | AAK1 (0.47) | HDAC1AAK1ALDH1A1MEN1KMT2A | |
| SCHEMBL38661718 | 0.85 | AAK1 (0.47) | HDAC1AAK1ALDH1A1MEN1KMT2A | |
| SCHEMBL5868970 | 0.85 | AAK1 (0.41) | HDAC1AAK1HSP90AA1HSP90AB1CYP17A1 | |
| SCHEMBL17616117 | 0.85 | KMT2A (0.52) | HSP90AA1HSP90AB1CYP17A1USP30NPC1 | |
| SCHEMBL3410364 | 0.84 | HPGD (0.49) | AAK1CYP17A1ALDH1A1 | |
| SCHEMBL15160030 | 0.84 | GAA (0.52) | AAK1CYP17A1NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118632841-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023067354-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| CN-113461602-B | Aniline compounds with HDAC (Histone deacetylase) inhibitory activity, preparation method, composition and application | 北京华氏信华科生物科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| EP-2751095-B1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-2751095-B1 | NOVEL BENZODIAZEPINONES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR FUNCTIONS AND NEUROLOGICAL USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113461602-A | Aniline compounds with HDAC (HDAC) inhibitory activity, preparation method, composition and application | 北京华氏信华科生物科技有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-111116469-A | HDAC inhibitor, preparation method, pharmaceutical composition and application thereof | 北京鑫开元医药科技有限公司 | 2020-05-08 | — | — | CN | disclosed |
| US-9193710-B2 | Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193710-B2 | Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193710-B2 | Benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-11-24 | — | — | US | disclosed |
| EP-1474416-B1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| EP-1651234-B1 | COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-7235547-B2 | Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist | HOFFMANN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1651234-A1 | COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050049243-A1 | Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist | HOFFMANN-LA ROCHE INC. | 2005-03-03 | — | — | US | disclosed |
| WO-2005014002-A1 | COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| EP-1474416-A1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
| WO-2003066623-A1 | DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049243-A1 | Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist | GRM2, GRIK2, GRIA2 | HDAC1 541/4885AAK1 1064/4885ABL1 3734/4885 |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | HDAC1 1172/4885AAK1 2928/4885ABL1 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.